Singapore markets open in 1 hour 13 minutes
Straits Times Index
3,202.81 -39.19 (-1.21%) S&P 500
4,330.00 -72.20 (-1.64%) Dow
34,070.42 -370.46 (-1.08%) Nasdaq
13,223.99 -245.14 (-1.82%) Bitcoin USD
26,563.48 -578.58 (-2.13%) CMC Crypto 200
566.31 -9.95 (-1.73%)
LianBio (LIAN)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 1.5400 |
| Open | 1.6082 |
| Bid | 1.4500 x 3000 |
| Ask | 1.5800 x 1200 |
| Day's range | 1.4700 - 1.6082 |
| 52-week range | 1.0700 - 2.9000 |
| Volume | |
| Avg. volume | 212,674 |
| Market cap | 160.752M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8000 |
| Earnings date | 10 Nov 2023 - 14 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.74 |
- MediaOutReach
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China
SHANGHAI, CHINA, and PRINCETON, N. J., USA - Media OutReach - 12 May 2023 - LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced yesterday that CAMZYOS ®(mavacamten) has received marketing approval for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from the Pharmaceutical Administration Bureau of the Macau SAR. "Hypertrophic cardiomyopathy is a cardiovascul
ZacksLianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China
As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments.
© 2023 Yahoo. All rights reserved.
